Activin and Inhibin

Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC 50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).In VivoLp-PLA2-IN-3 (3 mg/kg: p.o.) treatment shows the C max , AUC 0-24h ,

LPA2 antagonist 1 is a LPA2 antagonist with an IC 50 of 17 nM.In VitroLPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused

LPA2 antagonist 1 is a LPA2 antagonist with an IC 50 of 17 nM.In VitroLPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused

LPA2 antagonist 1 is a LPA2 antagonist with an IC 50 of 17 nM.In VitroLPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused

LPA2 antagonist 1 is a LPA2 antagonist with an IC 50 of 17 nM.In VitroLPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused

LPA2 antagonist 1 is a LPA2 antagonist with an IC 50 of 17 nM.In VitroLPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

LS-102 is a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC 50 of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment.In VitroLS-102 inhibits proliferation of

LS-102 is a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC 50 of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment.In VitroLS-102 inhibits proliferation of